Won-Jun Jang

Sang Hoon Joo1
Joydeb K Kundu1
Jong-Soon Kang1
Chul-Ho Jeong1
1Sang Hoon Joo
1Joydeb K Kundu
1Jong-Soon Kang
Learn More
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been introduced for the treatment of non-small cell lung cancer (NSCLC), the emergence of secondary T790M mutation in EGFR or amplification of the Met proto-oncogene restrain the clinical success of EGFR-TKIs. Since heat shock protein-90 (Hsp90) stabilizes various(More)
  • 1